MILAN — Contrary to indications from previous studies, there is no association between increased lipoprotein(a) concentrations and the risk for subsequent thrombotic events, suggests a new large-scale ...
The results of a recent retrospective analysis of electronic health record (EHR) data found that only 0.4% of patients with atherosclerotic cardiovascular disease (ASCVD) were tested for lipoprotein(a ...
CHICAGO — The remarkable and sustained reductions in lipoprotein(a) ( Lp[a]) achieved with lepodisiran (Eli Lilly) , a novel small-interfering (si)RNA molecule, in a phase 2 trial might signal a major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results